Cargando…

Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy

There is no consensus on whether it is safe to re-administer tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) flared after withdrawal of TNFα inhibitors due to active tuberculosis (TB). We evaluated the safety of restarting anti-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suh, Young Sun, Kwok, Seung-ki, Ju, Ji Hyeon, Park, Kyung-Su, Park, Sung-Hwan, Yoon, Chong-Hyeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890474/ https://www.ncbi.nlm.nih.gov/pubmed/24431903 http://dx.doi.org/10.3346/jkms.2014.29.1.38

Ejemplares similares

Erratum: Correction of Notes. Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)

Anti-TNF-α Therapy for Ankylosing Spondylitis
por: Son, Jung-Hwan, et al.
Publicado: (2010)

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
por: Jang, Dan-in, et al.
Publicado: (2021)

TNF-alpha antagonists for treatment of juvenile ankylosing spondylitis
por: Orbán, I, et al.
Publicado: (2011)

Association of anti-TNF-α treatment with gut microbiota of patients with ankylosing spondylitis
por: Dai, Qinghong, et al.
Publicado: (2022)

Age determines response to anti-TNFα treatment in patients with ankylosing spondylitis and is related to TNFα-producing CD8 cells
por: Schramm-Luc, Agata, et al.
Publicado: (2018)

Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice
por: Liu, Bin, et al.
Publicado: (2019)

Associations of Platelet Count with Inflammation and Response to Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis
por: Qian, Hongyan, et al.
Publicado: (2020)

Treatment of ankylosing spondylitis with TNFα inhibitors does not affect serum levels of tryptophan metabolites
por: Witoszyńska-Sobkowiak, Joanna, et al.
Publicado: (2023)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-α and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab
por: Schulz, Martin, et al.
Publicado: (2014)

Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?
por: Coşkun, Belkıs Nihan, et al.
Publicado: (2022)

Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients
por: Ciechomska, Marzena, et al.
Publicado: (2018)

Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology
por: Czókolyová, Monika, et al.
Publicado: (2021)

Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
por: Soós, Boglárka, et al.
Publicado: (2022)

TNF-α Induced the Enhanced Apoptosis of Mesenchymal Stem Cells in Ankylosing Spondylitis by Overexpressing TRAIL-R2
por: Liu, Zhenhua, et al.
Publicado: (2017)

Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-α inhibitors
por: Carbo, Marlies J. G., et al.
Publicado: (2018)

The relationship between blood eosinophil count and disease activity in ankylosing spondylitis patients treated with TNF-α inhibitors
por: Sargin, Gokhan, et al.
Publicado: (2018)

Rituximab Can Induce Remission in a Patient with Ankylosing Spondylitis Who Failed Anti-TNF-α Agent
por: AlDhaheri, Fahmi, et al.
Publicado: (2017)

Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor
por: Kwon, Oh Chan, et al.
Publicado: (2021)

Tumour Necrosis Factor Alpha (TNF-α) and Oral Squamous Cell Carcinoma
por: Brierly, Gary, et al.
Publicado: (2023)

Imbalance between HAT and HDAC Activities in the PBMCs of Patients with Ankylosing Spondylitis or Rheumatoid Arthritis and Influence of HDAC Inhibitors on TNF Alpha Production
por: Toussirot, Eric, et al.
Publicado: (2013)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches
por: Braun, Juergen, et al.
Publicado: (2002)

Immunological Changes in Peripheral Blood of Ankylosing Spondylitis Patients during Anti-TNF-α Therapy and Their Correlations with Treatment Outcomes
por: Chen, Rongjuan, et al.
Publicado: (2021)

Influence of anti-TNF-α treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study
por: Akyol, Lütfi, et al.
Publicado: (2022)

Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis
por: Wang, Ziran, et al.
Publicado: (2022)

Identification of Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking
por: Bai, Liang Liang, et al.
Publicado: (2021)

Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
por: Ou, Jiayong, et al.
Publicado: (2021)

The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis
por: Lee, Suhwan, et al.
Publicado: (2019)

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
por: Kekow, Joern, et al.
Publicado: (2012)

Polymorphisms in Tumour Necrosis Factor Alpha (TNFα) Gene in Patients with Acute Pancreatitis
por: Özhan, Gül, et al.
Publicado: (2010)

Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

Ceramide Kinase Regulates the Production of Tumor Necrosis Factor α (TNFα) via Inhibition of TNFα-converting Enzyme
por: Lamour, Nadia F., et al.
Publicado: (2011)

A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
por: Edgson, Lucy, et al.
Publicado: (2010)

Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
por: Fabbroni, Marta, et al.
Publicado: (2014)

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis
por: Liu, Wei, et al.
Publicado: (2016)

Genetic association between TNF-α −857 C/T polymorphism and ankylosing spondylitis susceptibility: evidence from a meta-analysis
por: Li, Yong, et al.
Publicado: (2016)

A prospective clinical investigation of the effects of anti-TNF alpha therapy on exercise capacity in patients with ankylosing spondylitis
por: ÇAPKIN, Erhan, et al.
Publicado: (2019)

The Role of TNFα in the Pathogenesis of Rheumatoid Synovitis
por: Maini, Ravinder N, et al.
Publicado: (2000)

TNF-α and TNF-β Gene Polymorphism in Saudi Rheumatoid Arthritis Patients
por: Al-Rayes, Hannan, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6fdnhl6i3tf1irgo0cto3s5nhi